Emsam: the first year.

We investigated the use of EMSAM in the first year post-launch in the US-April of 2006 through March of 2007. According to our data, EMSAM represents <0.1 percent of total prescriptions for antidepressants in the US and is prescribed most often by psychiatrists (83%of prescriptions). The impact of the product on the MAO inhibitor class, however, has been significant. We found that EMSAM now represents 30 percent of all MAO inhibitor use and has been a catalyst for growth in the overall MAO inhibitor class. An expert commentary is provided on the data.